Stock Research for CPRX

CPRX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CPRX Stock Chart & Research Data

The CPRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CPRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CPRX Due diligence Resources & Stock Charts

The CPRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CPRX Detailed Price Forecast - CNN Money CNN View CPRX Detailed Summary - Google Finance
Yahoo View CPRX Detailed Summary - Yahoo! Finance Zacks View CPRX Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View CPRX Trends & Analysis - Trade-Ideas Barrons View CPRX Major Holders - Barrons
NASDAQ View CPRX Call Transcripts - NASDAQ Seeking View CPRX Breaking News & Analysis - Seeking Alpha
Spotlight View CPRX Annual Report - CompanySpotlight.com OTC Report View CPRX OTC Short Report - OTCShortReport.com
TradeKing View CPRX Fundamentals - TradeKing Charts View CPRX SEC Filings - Bar Chart
WSJ View Historical Prices for CPRX - The WSJ Morningstar View Performance/Total Return for CPRX - Morningstar
MarketWatch View the Analyst Estimates for CPRX - MarketWatch CNBC View the Earnings History for CPRX - CNBC
StockMarketWatch View the CPRX Earnings - StockMarketWatch MacroAxis View CPRX Buy or Sell Recommendations - MacroAxis
Bullish View the CPRX Bullish Patterns - American Bulls Short Pains View CPRX Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View CPRX Stock Mentions - StockTwits PennyStocks View CPRX Stock Mentions - PennyStockTweets
Twitter View CPRX Stock Mentions - Twitter Invest Hub View CPRX Investment Forum News - Investor Hub
Yahoo View CPRX Stock Mentions - Yahoo! Message Board Seeking Alpha View CPRX Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for CPRX - SECform4.com Insider Cow View Insider Transactions for CPRX - Insider Cow
CNBC View CPRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CPRX - OTC Markets
Yahoo View Insider Transactions for CPRX - Yahoo! Finance NASDAQ View Institutional Holdings for CPRX - NASDAQ


Stock Charts

FinViz View CPRX Stock Insight & Charts - FinViz.com StockCharts View CPRX Investment Charts - StockCharts.com
BarChart View CPRX Stock Overview & Charts - BarChart Trading View View CPRX User Generated Charts - Trading View


Latest Financial News for CPRX

Catalyst Pharmaceuticals Appoints Daniel J. Brennan as Chief Commercial Officer
Posted on Wednesday June 13, 2018

Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of Daniel J. Brennan as Chief Commercial Officer. Mr. Brennan will be responsible for leading the Company’s marketing, sales and commercial operations as Catalyst prepares for a potential launch of Firdapse®. “We are pleased to welcome Dan to the Catalyst team, as he brings extensive experience in leading the commercial efforts at biopharmaceutical companies, particularly those focused on orphan, neurological diseases,” said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceuticals.


Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors
Posted on Tuesday June 12, 2018

Opiant Pharmaceuticals, Inc. ("Opiant") (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced the appointment of Richard J. Daly as a non-executive director and a member of the Audit Committee. Mr. Daly has supported the successful launch of 10 drugs during a 27-year career in the biotech and pharmaceutical industry.  With his appointment, the Opiant Board now consists of six members, four of whom are independent.


Catalyst Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
Posted on Thursday May 31, 2018

Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the Company will be presenting at the Jefferies 2018 Global Healthcare Conference, in New York. Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Wednesday, June 6 at 8:00 am ET.


Catalyst Pharmaceuticals Announces FDA Acceptance of NDA and Priority Review Status for Firdapse® (Amifampridine Phosphate) for Lambert-Eaton Myasthenic Syndrome
Posted on Tuesday May 29, 2018

Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, announced today that its New Drug Application (NDA) for Firdapse® for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) has been accepted for a Priority Review by the U.S. Food and Drug Administration (FDA). Priority Review is granted by the FDA to drugs with the potential to address a serious condition and, if approved, would provide a significant improvement in safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition.


Enter a stock symbol to view the stock details.